AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 163 filers reported holding AERIE PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 0.72 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,049,000 | +116.3% | 69,300 | +7.1% | 0.00% | – |
| Q2 2022 | $485,000 | -17.7% | 64,700 | 0.0% | 0.00% | – |
| Q1 2022 | $589,000 | +30.0% | 64,700 | +0.3% | 0.00% | – |
| Q4 2021 | $453,000 | -38.4% | 64,500 | 0.0% | 0.00% | – |
| Q3 2021 | $735,000 | -28.8% | 64,500 | 0.0% | 0.00% | – |
| Q2 2021 | $1,033,000 | -2.2% | 64,500 | +9.1% | 0.00% | – |
| Q1 2021 | $1,056,000 | +18.1% | 59,100 | -10.7% | 0.00% | – |
| Q4 2020 | $894,000 | +6.7% | 66,200 | -7.0% | 0.00% | – |
| Q3 2020 | $838,000 | -62.5% | 71,200 | -53.0% | 0.00% | -100.0% |
| Q2 2020 | $2,235,000 | -77.6% | 151,400 | -79.5% | 0.00% | -85.7% |
| Q1 2020 | $9,993,000 | -37.5% | 740,244 | +11.8% | 0.01% | -22.2% |
| Q4 2019 | $15,997,000 | +52.9% | 661,859 | +21.6% | 0.01% | +28.6% |
| Q3 2019 | $10,464,000 | -39.6% | 544,422 | -7.1% | 0.01% | -36.4% |
| Q2 2019 | $17,322,000 | -38.6% | 586,188 | -1.4% | 0.01% | -38.9% |
| Q1 2019 | $28,233,000 | +35.7% | 594,382 | +3.1% | 0.02% | +20.0% |
| Q4 2018 | $20,807,000 | -28.1% | 576,383 | +22.5% | 0.02% | -21.1% |
| Q3 2018 | $28,949,000 | +2.8% | 470,336 | +12.8% | 0.02% | -5.0% |
| Q2 2018 | $28,158,000 | +18.8% | 416,852 | -4.6% | 0.02% | +17.6% |
| Q1 2018 | $23,694,000 | +6.9% | 436,759 | +17.7% | 0.02% | +6.2% |
| Q4 2017 | $22,172,000 | +10.0% | 371,076 | -10.5% | 0.02% | +6.7% |
| Q3 2017 | $20,156,000 | +1.6% | 414,730 | +9.9% | 0.02% | 0.0% |
| Q2 2017 | $19,832,000 | +3.7% | 377,384 | -10.5% | 0.02% | 0.0% |
| Q1 2017 | $19,121,000 | +19.2% | 421,642 | -0.5% | 0.02% | +15.4% |
| Q4 2016 | $16,036,000 | +0.4% | 423,683 | +0.1% | 0.01% | 0.0% |
| Q3 2016 | $15,969,000 | +45.7% | 423,122 | -32.1% | 0.01% | +44.4% |
| Q2 2016 | $10,962,000 | +63.4% | 622,839 | +12.9% | 0.01% | +50.0% |
| Q1 2016 | $6,708,000 | -47.7% | 551,638 | +4.8% | 0.01% | -45.5% |
| Q4 2015 | $12,817,000 | +2398.4% | 526,374 | +1721.4% | 0.01% | – |
| Q3 2015 | $513,000 | +24.8% | 28,900 | +24.0% | 0.00% | – |
| Q2 2015 | $411,000 | +95.7% | 23,300 | +247.8% | 0.00% | – |
| Q1 2015 | $210,000 | +320.0% | 6,700 | +294.1% | 0.00% | – |
| Q4 2014 | $50,000 | -28.6% | 1,700 | -50.0% | 0.00% | – |
| Q3 2014 | $70,000 | -16.7% | 3,400 | 0.0% | 0.00% | – |
| Q2 2014 | $84,000 | – | 3,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 246,563 | $2,244,000 | 1.36% |
| LEVIN CAPITAL STRATEGIES, L.P. | 1,435,876 | $13,066,000 | 1.26% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 4,695,020 | $42,725,000 | 0.96% |
| DCF Advisers, LLC | 189,565 | $1,725,000 | 0.76% |
| DAFNA Capital Management LLC | 289,040 | $2,630,000 | 0.68% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,678,609 | $15,275,000 | 0.61% |
| Rhenman & Partners Asset Management AB | 589,200 | $5,362,000 | 0.53% |
| PFM Health Sciences, LP | 1,088,566 | $9,906,000 | 0.37% |
| NEXPOINT ASSET MANAGEMENT, L.P. | 309,778 | $2,819,000 | 0.36% |
| Granahan Investment Management | 1,588,944 | $14,459,000 | 0.36% |